AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00107-07v1
51/7/2625    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shin, J. H.
Right arrow Articles by Chang, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shin, J. H.
Right arrow Articles by Chang, C. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2007, p. 2625-2627, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00107-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Prevalence, Characteristics, and Molecular Epidemiology of Macrolide and Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae at Five Tertiary-Care Hospitals in Korea{triangledown}

Jeong Hwan Shin,1,2* Hee Jung Jung,1,2 Hye Ran Kim,1 Joseph Jeong,3 Seok Hoon Jeong,4 Sunjoo Kim,5 Eun Yup Lee,6 Jeong Nyeo Lee,1,2 and Chulhun Ludgerus Chang6,7

Department of Laboratory Medicine,1 Paik Institute for Clinical Research, College of Medicine, Inje University, Busan,2 Department of Laboratory Medicine, College of Medicine, Ulsan University, Ulsan,3 Department of Laboratory Medicine, College of Medicine, Kosin University, Busan,4 Department of Laboratory Medicine, School of Medicine, Gyeongsang National University, Jinju,5 Department of Laboratory Medicine, School of Medicine,6 Medical Research Institute, Pusan National University, Busan, Korea7

Received 24 January 2007/ Returned for modification 21 March 2007/ Accepted 7 May 2007


   ABSTRACT
Top
 ABSTRACT
TEXT
 REFERENCES
 
The genes erm(B), mef(A), and both erm(B) and mef(A) were identified in 42.6, 10.1, and 47.3%, respectively, of the erythromycin-resistant Streptococcus pneumoniae isolates. Of the strains, 3.8% were nonsusceptible to levofloxacin and had 1 to 6 amino acid changes in the quinolone resistance-determining region, including a new mutation, Asn94Ser, in the product of parC. Levofloxacin with reserpine was highly specific for efflux screening.


   TEXT
Top
 ABSTRACT
 TEXT
REFERENCES
 
The increase in the resistance of Streptococcus pneumoniae to primary antibiotic agents has become a serious problem (1). Previous reports documented high rates of penicillin and erythromycin resistance among clinical isolates from Asia with the spread of the Taiwan19F and the Spain23F clones (19). Fluoroquinolones are now recommended for the empirical treatment of S. pneumoniae infection (9). Although increasing rates of resistance have been described in a few previous reports, the rate of fluoroquinolone resistance among S. pneumoniae isolates remains low worldwide (4, 7, 14, 15, 17). We describe the antimicrobial susceptibility of S. pneumoniae to commonly used antimicrobial agents and focus on the prevalence of genotypes and the molecular epidemiology of macrolide and fluoroquinolone resistance among isolates of S. pneumoniae from five tertiary-care hospitals in Korea.

A total of 235 isolates of S. pneumoniae were collected from five tertiary-care hospitals between 2002 and 2006. The organisms were isolated from the lower respiratory tract (68.5%), blood (14.9%), the upper respiratory tract (6.8%), the ear (3.4%), pus (2.6%), the eye (1.7%), and other sites (2.1%). Antimicrobial susceptibility testing was performed using the broth microdilution method, and results were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (5, 6). The S. pneumoniae ATCC 49619 strain was used as a control. The bacterial genomic DNA was prepared with a genomic DNA preparation kit (Solgent Co., Daejeon, Korea). The PCRs for macrolide resistance genes and mutations in the quinolone resistance-determining region (QRDR) were performed with the primers listed in Table 1. The purified DNA was sequenced with the ABI PRISM 3130xl genetic analyzer (Applied Biosystems, Foster City, CA). The efflux phenotype was inferred from a fourfold or greater reduction in the MICs of any of the three fluoroquinolones (norfloxacin, ciprofloxacin, and levofloxacin) tested in the presence of reserpine (10 µg/ml; Sigma, St. Louis, MO). A reverse transcriptase PCR was performed to detect pmrA expression (12). Multilocus sequence typing and serotyping by Pneumotest-Latex (Statens Serum Institut, Copenhagen, Denmark) were conducted with nine levofloxacin-nonsusceptible isolates to assess clonality.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Primers of macrolide and fluoroquinolone resistance genes used in this study

 
Antimicrobial susceptibility results. The rate of resistance to penicillin was 67.2%. The highest rates of resistance were those to erythromycin (80%) and tetracycline (81.3%) (Table 2). Nine strains (3.8%) were nonsusceptible to levofloxacin, with seven resistant and two intermediate, and 185 isolates (78.7%) were multidrug resistant.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Susceptibility of 235 isolates of S. pneumoniae collected from five tertiary-care hospitals in Korea to 12 agents

 
Distribution of macrolide resistance genes and QRDR mutations. The genes erm(B), mef(A), and both erm(B) and mef(A) were identified in 42.6, 10.1, and 47.3% of the erythromycin-resistant isolates. No erm(TR)-positive isolates were detected. Levofloxacin-nonsusceptible strains had 1 to 6 amino acid changes in the QRDRs, including a new mutation, Asn94Ser, in the product of parC (Table 3). All of the levofloxacin-nonsusceptible strains contained an Ile460Val alteration in the product of parE. Three isolates possessed only 1 amino acid substitution within the product of parE. The clonal profile in general was heterogeneous, although a few isolates may have a clonal relation.


View this table:
[in this window]
[in a new window]

  		TABLE 3. QRDR mutations, results of multilocus sequence typing, serotypes, and efflux phenotypes characterizing nine levofloxacin-nonsusceptible S. pneumoniae isolates

 
Reserpine efflux screening and pmrA expression. Among the 235 isolates, 177 showed an efflux phenotype (norfloxacin, n = 134 [57.0%]; ciprofloxacin, n = 109 [46.4%]; and levofloxacin, n = 7 [3.0%]). Among nine levofloxacin-nonsusceptible isolates, an efflux phenotype corresponding to norfloxacin, ciprofloxacin, and levofloxacin was detected in three, six, and five strains, respectively. Only 2 of 226 levofloxacin-susceptible isolates exhibited the efflux phenotype when levofloxacin was used with reserpine (MIC, 2 µg/ml). All three isolates showing only a parE mutation had an efflux phenotype. Among the isolates showing an efflux phenotype, 85.4% expressed the pmrA gene.

These study results indicate high rates of resistance of S. pneumoniae to many antimicrobial agents and an uncommon increase in levofloxacin resistance in Korea. We ascertained that the presence of both erm(B) and mef(A) was highly related to multidrug resistance, as Brown et al. reported previously (3). All levofloxacin-nonsusceptible isolates had an Ile460Val alteration in the product of parE, with three isolates showing this change as the only substitution. This finding differs from results in previous reports. The high prevalence of a single Ile460Val mutation in the parE product was also described in a previous report (18), but the authors of that study reported that all except 1 of 78 isolates with a single parE mutation were susceptible to levofloxacin. We presume that the high-level levofloxacin resistance of isolates with parE-only mutations was associated with efflux pump mechanisms (see below). The numerous QRDR mutations may not have any major effect on the fluoroquinolone MICs, as noted in a previous report (3).

It is considered that for S. pneumoniae, ciprofloxacin is the drug most susceptible to efflux mechanisms (2, 7, 13, 21). In this study, efflux mechanisms were also found more commonly when efflux screening was performed with norfloxacin or ciprofloxacin than when levofloxacin was used. However, for the fluoroquinolone-nonsusceptible isolates, levofloxacin was superior to norfloxacin and similar to ciprofloxacin in detecting an efflux phenotype. Moreover, the majority of strains that were positive for an efflux phenotype active with ciprofloxacin or norfloxacin were characterized as susceptible by levofloxacin susceptibility testing. In almost all previous reports, norfloxacin- or ciprofloxacin-resistant strains were used to study the fluoroquinolone resistance mechanism of S. pneumoniae and norfloxacin or ciprofloxacin was used to study the reserpine-sensitive efflux mechanism. If the low rate of levofloxacin resistance among S. pneumoniae strains in the world is considered, there is a significant likelihood that no or very few isolates of levofloxacin-resistant S. pneumoniae were included in previous studies. Neither norfloxacin nor ciprofloxacin is recommended for respiratory infections caused by S. pneumoniae, and those drugs are not included in the CLSI guidelines for S. pneumoniae. From this result, we can infer that levofloxacin is the most appropriate and highly specific drug for efflux screening for high-level levofloxacin resistance. Brown et al. (3) thought that parE might play a greater role in high-level fluoroquinolone resistance. In the present study, we obtained similar results but found that all three isolates showing only the parE mutation had an efflux phenotype. This efflux mechanism may play a greater role in high-level fluoroquinolone resistance along with the QRDR mutations.


   ACKNOWLEDGMENTS
 
This work was supported by a 2005 Inje University grant for the research institute.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Laboratory Medicine, College of Medicine, Inje University, 633-165 Gaegeum-Dong Busanjin-Gu, Busan, 614-110, Korea. Phone: 82-51-890-6475. Fax: 82-51-893-1562. E-mail: jhsmile{at}inje.ac.kr Back

{triangledown} Published ahead of print on 14 May 2007. Back


   REFERENCES
Top
 ABSTRACT
 TEXT
 REFERENCES
 

  1. Appelbaum, P. C. 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34:1613-1620.[CrossRef][Medline]
  2. Broskey, J., K. Coleman, M. N. Gwynn, L. McCloskey, C. Traini, L. Voelker, et al. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. 1):95-99.[Abstract/Free Full Text]
  3. Brown, S. D., D. J. Farrell, and I. Morrissey. 2004. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J. Clin. Microbiol. 42:4980-4987.[Abstract/Free Full Text]
  4. Canton, R., M. Morosini, M. C. Enright, and I. Morrissey. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52:944-952.[Abstract/Free Full Text]
  5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
  6. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
  7. Ho, P. L., R. W. Yung, D. N. Tsang, T. L. Que, M. Ho, W. H. Seto, et al. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.[Abstract/Free Full Text]
  8. Janoir, C., V. Zeller, M. D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.[Abstract]
  9. Mandell, L. A., J. G. Bartlett, S. F. Dowell, T. M. File, Jr., D. M. Musher, and C. Whitney. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37:1405-1433.[CrossRef][Medline]
  10. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.[Abstract]
  11. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.[Abstract]
  12. Piddock, L. J., M. M. Johnson, S. Simjee, and L. Pumbwe. 2002. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:808-812.[Abstract/Free Full Text]
  13. Piddock, L. J., M. Johnson, V. Ricci, and S. L. Hill. 1998. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob. Agents Chemother. 42:2956-2960.[Abstract/Free Full Text]
  14. Powis, J., A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, et al. 2004. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48:3305-3311.[Abstract/Free Full Text]
  15. Quale, J., D. Landman, J. Ravishankar, C. Flores, and S. Bratu. 2002. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg. Infect. Dis. 8:594-597.[Medline]
  16. Reig, M., J. Galan, F. Baquero, and J. C. Perez-Diaz. 2001. Macrolide resistance in Peptostreptococcus spp. mediated by ermTR: possible source of macrolide-lincosamide-streptogramin B resistance in Streptococcus pyogenes. Antimicrob. Agents Chemother. 45:630-632.[Abstract/Free Full Text]
  17. Reinert, R. R., S. Reinert, M. van der Linden, M. Y. Cil, A. Al-Lahham, and P. Appelbaum. 2005. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49:2903-2913.[Abstract/Free Full Text]
  18. Richter, S. S., K. P. Heilmann, S. E. Beekmann, N. J. Miller, C. L. Rice, and G. V. Doern. 2005. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin. Infect. Dis. 40:225-235.[CrossRef][Medline]
  19. Song, J. H., S. I. Jung, K. S. Ko, N. Y. Kim, J. S. Son, H. H. Chang, et al. 2004. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 48:2101-2107.[Abstract/Free Full Text]
  20. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
  21. Zhanel, G. G., A. Walkty, K. Nichol, H. Smith, A. Noreddin, and D. J. Hoban. 2003. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn. Microbiol. Infect. Dis. 45:63-67.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, July 2007, p. 2625-2627, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00107-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00107-07v1
51/7/2625    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shin, J. H.
Right arrow Articles by Chang, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shin, J. H.
Right arrow Articles by Chang, C. L.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS